Could a vaccine help prevent cervical cancer return? early trial shows promise
NCT ID NCT02405221
First seen Oct 31, 2025 · Last updated May 15, 2026 · Updated 27 times
Summary
This early study tested the safety and feasibility of the TA-CIN vaccine in 15 people who had been treated for HPV16-related cervical cancer and were cancer-free at the time. The goal was to see if the vaccine could be given safely and whether it triggered an immune response that might help prevent the cancer from coming back. The study focused on finding the right dose and checking for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HPV16 ASSOCIATED CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, 21287, United States
-
Women & Infants Center, University of Alabama at Birmingham
Birmingham, Alabama, 35233, United States
Conditions
Explore the condition pages connected to this study.